PSA – targeting the men at highest risk

A move towards targeted screening of men at higher risk of prostate cancer offers the potential to improve outcomes. In this article, members of the Prostate Cancer UK Education Advisory Group outline ways in which primary care physicians can ensure that PSA testing is targeted at those who are most likely to benefit.

[1]  T. Tammela,et al.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.

[2]  L. Kiemeney,et al.  Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study , 2014, European urology.

[3]  M. Bultitude,et al.  The management of lower urinary tract symptoms in men , 2014, BMJ : British Medical Journal.

[4]  Ali Amin Al Olama,et al.  The genetic epidemiology of prostate cancer and its clinical implications , 2014, Nature Reviews Urology.

[5]  R. Karnes,et al.  Men (aged 40-49 years) with a single baseline prostate-specific antigen below 1.0 ng/mL have a very low long-term risk of prostate cancer: results from a prospectively screened population cohort. , 2013, Urology.

[6]  G. Kristiansen,et al.  Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial. , 2013, European urology.

[7]  Walter Artibani,et al.  Early detection of prostate cancer: European Association of Urology recommendation. , 2013, European urology.

[8]  R. Eeles,et al.  Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Scardino,et al.  Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study , 2013, BMJ : British Medical Journal.

[10]  T. Wilt,et al.  Prostate cancer screening and the management of clinically localized disease , 2013, BMJ.

[11]  Anssi Auvinen,et al.  Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). , 2012, European urology.

[12]  V. Moyer,et al.  Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[13]  S. Loeb.  Use of baseline prostate-specific antigen measurements to personalize prostate cancer screening. , 2012, European urology.

[14]  F. Hamdy,et al.  Prostate‐specific antigen testing rates remain low in UK general practice: a cross‐sectional study in six English cities , 2011, BJU international.

[15]  P. Scardino,et al.  Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate‐specific antigen at or before age 50 , 2011, Cancer.

[16]  F. Schröder,et al.  The influence of family history on prostate cancer risk: implications for clinical management , 2011, BJU International.

[17]  D. Gillatt,et al.  Pathways to diagnosis for Black men and White men found to have prostate cancer: the PROCESS cohort study , 2008, British Journal of Cancer.

[18]  Y. Ben-Shlomo,et al.  Investigating Black‐White differences in prostate cancer prognosis: A systematic review and meta‐analysis , 2008, International journal of cancer.

[19]  David Gillatt,et al.  The risk of prostate cancer amongst black men in the United Kingdom: the PROCESS cohort study. , 2007, European urology.

[20]  G. Muir,et al.  Racial origin is associated with poor awareness of prostate cancer in UK men, but can be increased by simple information , 2007, Prostate Cancer and Prostatic Diseases.

[21]  M. Roobol,et al.  Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). , 2005, Urology.

[22]  P. Engstrom,et al.  Relative risk of prostate cancer for men with affected relatives: Systematic review and meta‐analysis , 2003, International journal of cancer.

[23]  P. Ewings,et al.  The development and validation of a quality‐of‐life measure to assess partner morbidity in benign prostatic enlargement , 2000, BJU international.

[24]  P. Scardino,et al.  Early detection of prostate cancer. , 1989, The Urologic clinics of North America.